# Progress Note 06 — Focused Visit (Care-plan review)

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Elizabeth I (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-RE003-SYN-TD
- Date: 1603-03-16
- Fictional facility: St. Posthumous Health Center
- Fictional author: Philippa Ashcombe-Nwosu, MD
- Calendar frame: true historical dates (modern content is anachronistic)

> True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

- Visit type: Focused Visit (Care-plan review)

## Chief complaint

Seven-week depression treatment review. **S**

## History of present illness

Ms. Tudor returns seven weeks after starting sertraline, now six weeks at 50 mg. She has had six sessions of interpersonal psychotherapy and has been able, for the first time, to talk about the friend she lost two years ago and her part in the breach between them. Her mood is lighter on most days; she has resumed audiences on most mornings, played music twice, and seen two old friends. She sleeps about five and a half hours. Her new partial denture is to be fitted next week, and she eats more, though still slowly. She has had no side effects, no falls, and no thoughts of death or self-harm. **S**

| Element | Detail |
|---|---|
| Medication | Sertraline 50 mg for six weeks; no side effects |
| Psychotherapy | Six IPT sessions, focused on grief |
| Sleep | About five and a half hours; Insomnia Severity Index 11 |
| Function | Audiences most mornings; music and friends again |
| Safety | No suicidal thoughts |
| PHQ-9 | 8, down from 17 |

## Review of systems

| System | Result | Finding |
|---|---|---|
| Constitutional | Positive | Appetite better; weight 53.4 kg |
| Gastrointestinal | Negative | No nausea, diarrhea, or bleeding |
| Musculoskeletal | Negative | No falls; shoulder ache settled |
| Psychiatric | Positive | Mood lighter but not yet back to her usual; no suicidal thoughts, elevated mood, or agitation |

4 systems reviewed. **S**

## Current medications

- Sertraline 50 mg oral tablet, one tablet by mouth each morning **S**

## Allergies

- No known allergy **S**

## Objective

BP 124/72 mmHg; pulse 70 bpm; respirations 14/min; temperature 36.5 °C; oxygen saturation 98% on room air; weight 53.4 kg; BMI 20.1 kg/m². All vital signs are synthetic.

PHQ-9: 8; GDS-15: 4. All results are synthetic.

## Change since baseline

- PHQ-9: 17 at baseline, 8 at this visit **S**
- GDS-15: 10 at baseline, 4 at this visit **S**

## Physical examination

| System | Finding |
|---|---|
| General | Thin but better nourished; animated |
| Mental status | Warm and engaged; normal pace of speech; mood "much lighter"; affect reactive; no suicidal ideation; no psychotic features |
| Cardiovascular | Blood pressure 124/72 mmHg seated, no orthostatic drop; pulse 70 |
| Musculoskeletal | Timed Up and Go 10 seconds |

All examination findings are synthetic. **S**

## Assessment and plan

1. **Major depressive disorder, single episode, moderate** (F32.1). PHQ-9 8, 53 percent below baseline, and GDS-15 4: a response, not yet remission, after seven weeks of combined sertraline and IPT. No side effects; no suicidal thoughts. **S**
   - Continue sertraline 50 mg and weekly IPT.
   - Review in four weeks, at about twelve weeks of treatment; if the PHQ-9 is still 5 or more, increase sertraline to 75 mg.
   - Once in remission, continue sertraline for at least six to twelve months before a slow taper.
   - Safety plan kept; 988 Suicide & Crisis Lifeline confirmed.
2. **Chronic insomnia comorbid with depression** (G47.00). Insomnia Severity Index 11, down from 19. **S**
   - Widen the sleep window by another 15 minutes.
3. **Partial loss of teeth with an ill-fitting partial denture** (K08.409). New denture to be fitted next week. **S**
   - Dietitian review of protein and energy intake after the denture is fitted.
4. **Fall risk** (Z91.81). No falls; Timed Up and Go 10 seconds. The DXA ordered at the wellness visit has not yet been done. **S**
   - DXA booked for next week.
   - Continue the balance class.

## Protocol monitoring

Items the monitoring protocol calls for at this visit. **S**

| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Survey | PHQ-9 | Baseline, then at least monthly during acute treatment; every 2 to 4 weeks in continuation | Completed today | 8, down from 17 (53 percent): response; remission is PHQ-9 below 5 |
| Survey | GDS-15 | Baseline and to monitor response in adults 65 or older (monthly here) | Completed today | 4, below the cutoff of 5 |
| Survey | Suicide risk reassessment (C-SSRS Since Last Visit and PHQ-9 item 9) | Every visit during active treatment | Completed today | No suicidal thoughts, intent, plan, or behavior; PHQ-9 item 9 scored 0 |
| Laboratory | Sodium on an SSRI | After starting, after dose increases, and with symptoms | Not indicated | 136 mmol/L four weeks after starting; no dose change and no confusion, nausea, or unsteadiness |
| Medication safety | Adherence and adverse-effect review | Every visit during active treatment | Completed today | No missed doses; no side effects |
| Referral | Interpersonal psychotherapy | Weekly | Completed today | Six sessions; grief focus |
| Examination | Weight and nutrition | Every visit while weight is below her usual | Completed today | 53.4 kg, up 1.0 kg since the diagnosis visit; usual weight 55.9 kg |
| Examination | Fall risk on an SSRI: orthostatic blood pressure, gait, and falls since the last visit | At baseline, after starting an SSRI, and with dose changes | Completed today | No falls; no orthostatic drop; Timed Up and Go 10 seconds |
| Imaging | DXA of the hip and spine | Once for women 65 or older; ordered at the wellness visit | Due | Booked for next week; no result yet |
| Self-management | Sleep (CBT-I), activity, and social contact | Every visit during active treatment | Completed today | Insomnia Severity Index 11; audiences, music, and friends resumed |
| Laboratory | Lithium, anticonvulsant, or antipsychotic monitoring (levels, metabolic tests, AIMS) | Only on those drugs | Not indicated | Treated with an SSRI only |

## Goal progress

- Medical causes of low mood and weight loss excluded by the second visit. Outcome by 1603-01-26: Blood count, metabolic panel, calcium, albumin, TSH, vitamin B12, folate, and MoCA normal; diphenhydramine stopped. **S**
- Response (PHQ-9 down by at least 50 percent) by twelve weeks of treatment, then remission (PHQ-9 below 5). In progress; target 1603-04-20. **S**
- No passive or active suicidal thoughts. Outcome by 1603-01-26: Passive death wish at intake only; PHQ-9 item 9 scored 0 from the second visit. **S**
- Sleep at least six hours most nights without hypnotics. In progress; target 1603-04-20. **S**
- Weight back to at least 55 kg, with a comfortable denture. In progress; target 1603-06-15. **S**

## Guideline basis

- APA Clinical Practice Guideline for the Treatment of Depression Across Three Age Cohorts (2019), American Psychological Association
- VA/DoD Clinical Practice Guideline for the Management of Major Depressive Disorder (2022), United States Department of Veterans Affairs and Department of Defense
- VA/DoD Clinical Practice Guideline for Assessment and Management of Patients at Risk for Suicide (2024), United States Department of Veterans Affairs and Department of Defense
- CMID: Clinical Monitoring Intelligence Database, depression, bipolar, and mood disorders monograph (2026), Aether Forge
- American Geriatrics Society 2023 Updated AGS Beers Criteria for Potentially Inappropriate Medication Use in Older Adults (2023), American Geriatrics Society (Journal of the American Geriatrics Society)
- Management of Chronic Insomnia Disorder in Adults: A Clinical Practice Guideline From the American College of Physicians (2016), American College of Physicians (Annals of Internal Medicine)
- Osteoporosis to Prevent Fractures: Screening (2025), U.S. Preventive Services Task Force

## Follow-up

- Depression review in four weeks, at about twelve weeks of treatment. **S**

